BREAKING NEWS: MT Pharma America, Inc. Announces Approval of RADICAVA

If you haven't already heard, MT Pharma America, Inc. just released some of the best news the ALS community could have asked for: the approval of RADICAVA, the second treatment available for ALS patients. Our founder, Jodi, and her deceased husband Kevin rallied for Riluzole, the first ALS treatment, over 20 years ago. For Jodi, being able to witness this progress in her lifetime was incredible. All of us affected by ALS truly have something to be cheering about. Thank you to the FDA for approving this drug in record-time, so that all pALS can receive the treatment as soon as possible.